Back to Search
Start Over
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
- Source :
- Clinical genitourinary cancer. 15(5)
- Publication Year :
- 2017
-
Abstract
- This article highlights the possible role of “patient-reported outcomes” in the evaluation of a new therapy. Abiraterone acetate is a novel treatment for metastatic prostate cancer characterized by good safety and oncologic efficacy. Few studies have investigated patients' satisfaction with treatment. Our data show that abiraterone acetate is associated with good satisfaction with treatment and that patient's satisfaction can be a predictor of good oncologic outcomes. Introduction Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. Materials and Methods This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death, or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. Eastern Cooperative Oncology Group score, pain symptoms, treatment-related toxicity, prostate-specific antigen (PSA), and overall and progression-free survival were recorded. Satisfaction with treatment was investigated at 6 months by means of a 4-point arbitrary scale. Results One-hundred twenty-eight patients were enrolled. Patients' satisfaction with treatment was “greatly improved” in 36.1% of patients and “improved” in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (P < .05), lower PSA levels at 12 weeks (P = .080), and less pain symptoms and lower Brief Pain Inventory scores (P = .001). Satisfaction with treatment was significantly correlated with baseline PSA level (P = .018), presence of pain (P = .007), duration of androgen deprivation therapy >12 months (P = .025), and number of hormonal manipulations (P = .051). Progression-free survival significantly correlated with patient satisfaction (P < .001). Conclusion AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PROs. Patient's satisfaction is a predictor of progression-free survival.
- Subjects :
- Oncology
Male
medicine.medical_specialty
abiraterone acetate
androgen deprivation therapy
castration-resistant prostate cancer
metastatic prostate cancer
patient reported outcomes
Urology
030232 urology & nephrology
Abiraterone Acetate
Antineoplastic Agents
Androgen deprivation therapy
Castration-Resistant
Disease-Free Survival
Metastatic prostate cancer
03 medical and health sciences
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Patient satisfaction
Quality of life
Internal medicine
80 and over
medicine
Humans
Brief Pain Inventory
Patient reported outcomes
Castration-resistant prostate cancer
Aged
Retrospective Studies
Aged, 80 and over
Abiraterone acetate
Disease Progression
Patient Satisfaction
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant
Quality of Life
Treatment Outcome
business.industry
Prostatic Neoplasms
Retrospective cohort study
medicine.disease
Patient reported outcome
Prostate-specific antigen
Settore MED/24
chemistry
030220 oncology & carcinogenesis
business
Subjects
Details
- ISSN :
- 19380682
- Volume :
- 15
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Clinical genitourinary cancer
- Accession number :
- edsair.doi.dedup.....33a2baa66d2fac7bc7cca437fc99c6df